INSIGHTS ON DRUG DEVELOPMENT
-
API In Capsule Vs. The Lost Art Of Formulation Development
API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.
-
Chemoenzymatic N-glycan Conjugation Of Native mAbs Provides Homogeneous, Efficacious ADCs
A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.
-
The Patent Cliff Looms – Design Your Biosimilar Approach Accordingly
In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.
-
Recombinant Protein Process Development And Scale-Up
Discover a resin for recombinant protein purification with a standardized protocol that streamlines workflows from lab to production, which saves time and enhances efficiency across development stages.
-
Characterization And Impurity Profiling Of Combined Amylin And GLP-1 Analogs7/29/2025
GLP-1 receptor agonists are transforming diabetes and weight loss treatment. Discover how to enable precise impurity analysis and characterization of complex, fatty acid-modified peptide therapeutics.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Overcoming Excipient Risks And Challenges For Parenteral Formulations8/27/2025
Excipients are essential to parenteral formulations, which help protect APIs, enhance stability, and ensure safety. Learn how strategic excipient selection can optimize drug performance and patient outcomes.
-
Improving Consumer Safety Through Innovative Science6/27/2025
Liquid chromatography revolutionizes science with precision. Discover a technology that leads the charge in enhancing HPLC performance for breakthroughs in health, safety, and environmental research.
-
mTOR Pathway3/24/2025
Explore the mTOR signaling pathway and reveal how mTORC1 regulates cell growth, metabolism, and survival to ensure cellular function and adaptation to environmental cues.
DRUG DEVELOPMENT SOLUTIONS
-
Our custom expression platform directly addresses the primary host limitations in early-to-mid stage assay development:
-
Rules-Based Fragment Prediction for Mass Spectrometry
ACD/MS Fragmenter helps you predict mass spectral fragmentation in seconds. Have more confidence in your compound IDs, learn about fragmentation mechanisms, and publish your results easily.
It’s as simple as this:
- Draw your compound
- Select the ionization polarity and fragmentation options
- View its fragmentation tree
-
As part of Stevanato Group’s commitment to R&D, our analytical testing facilities focus on investigating physico-chemical properties of primary packaging materials and components and studying the interactions between container closure system and drugs. Stevanato Group relies on a multi-disciplinary team of highly skilled professionals, including, scientists, engineers, pharmaceutical chemists and biotechnologists. Their knowledge and experience covers a range of specialized areas including container closure systems and drug-delivery devices.
-
An oral solid pilot plant paired with pharmaceutical technology and analytical development labs, built inside a commercial production campus, supports work through clinical batches and small-scale commercial supply.
-
Enhance tablet effectiveness across various dosages with an excipient that offers excellent compressibility and stability for APIs, which eliminates the need for intense processing and provides rapid disintegration.